EFFICIENCY OF LICOPID IN THE PATIENTS WITH CHRONIC ABACTERIAL PROSTATITIS COMPLICATED WITH FERTILITY DISORDERS

• Main Authors: A. V. Semyonov, N. Yu. Sotnikova, A. A. Martenova
• Format: Article
• Language: Russian
• Published: SPb RAACI 2014-07-01
• Series: Medicinskaâ Immunologiâ
• Subjects: male infertility; sperm morphology; chronic abacterial prostatitis; licopid; mononuclear cells; pathogen-associated molecular patterns
• Online Access: https://www.mimmun.ru/mimmun/article/view/201

Abstract. The study was aimed for evaluation of clinical and immunological efficiency of an immunomodulating drug Licopid (Peptec «CJSC») in chronic abacterial prostatitis (CAP) accompanied by fertility alterations. Licopid contains N-acetylglucoseaminil-β1-4-acetylmuramoyl-L-alanyl-D-isoglutamine (GMDP) which mimics a minimal repeated peptidoglycan structural unit from bacterial cell wall, and it represents a pathogen-associated molecular pattern, able to influence the innate immune system via appropriate pattern-recognition receptors. Thirty-eight infertile patients with azoospermia were under observation (20 to 45 years old, a mean of 28.84±1.1). CAP was diagnosed in accordance with NIH criteria, as chronic prostatitis of III-A category. Clinical examination included sperm analysis, using WHO criteria, and phenotyping of peripheral blood mononuclear cells, by the means of standard flow cytometry (FACScan, «Becton Dickinson»). A control group consisted of eight fertile males 21 to 33 years old (a mean of 26.8±2.33) with normozoospermia. For twenty-four randomly selected patients (main group), a treatment with Licopid was applied (a total of 100 mg, at a daily oral dose of 10 mg), in addition to common therapeutic schedule (fluorochinolones, α-adrenoblockers). A comparison group included fourteen patients receiving common therapy. Some differences in immune response were detectable in the CAP patients. Along with balanced («intense») state of immunity revealed in 16 subjects, 22 persons did exhibit a systemic immunosuppression which manifested as alterations in MNC activation and decreasing efficiency of the standard treatment. Licopid seems to be a drug of choice for these cases, due to decreased CAP activity and normalization of a spermogram following its application. Differentiated administration of immune modulating drugs will allow prevention of adverse effects of empirical immunocorrection.